The role of RB1 alteration and 4q12 amplification in IDH-WT glioblastoma.
Antonio DonoArvind V RameshEmily WangMauli ShahNitin TandonLeomar Y BallesterYoshua EsquenaziPublished in: Neuro-oncology advances (2021)
RB1-mutant GBM IDH-WT is a molecular subgroup with improved PFS and OS. Meanwhile, 4q12 amplification (KDR/PDGFRA/KIT) denoted patients with worse OS. Identifying subgroups of GBM IDH-WT with distinct survival is important for optimal clinical trial design, incorporation of targeted therapies, and personalized neuro-oncological care.